Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

labcorp holdings inc. - LH

LH

Close Chg Chg %
266.04 -0.03 -0.01%

Closed Market

266.01

-0.03 (0.01%)

Volume: 474.96K

Last Updated:

Mar 25, 2026, 3:59 PM EDT

Trade Now

Company Overview: labcorp holdings inc. - LH

LH Key Data

Open

$267.74

 Day Range

265.47 - 269.97

52 Week Range

209.38 - 293.72

 Market Cap

$21.93B

Shares Outstanding

82.40M

 Public Float

82.10M

Beta

1.01

 Rev. Per Employee

N/A

P/E Ratio

25.44

 EPS

$10.54

Yield

108.22%

 Dividend

$0.72

EX-DIVIDEND DATE

Feb 27, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

542.62K

  

LH Performance

1 Week
 
 1.19%
 
1 Month
 
 -7.96%
 
3 Months
 
 4.82%
 
1 Year
 
 15.69%
 
5 Years
 
 23.81%
 

LH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 20
Full Ratings ➔

About labcorp holdings inc. - LH

Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

LH At a Glance

Labcorp Holdings, Inc.
358 South Main Street
Burlington, North Carolina 27215-5837
Phone 1-336-229-1127 Revenue 13.95B
Industry Medical/Nursing Services Net Income 876.50M
Sector Health Services 2025 Sales Growth 7.247%
Fiscal Year-end 12 / 2026 Employees 71,000
View SEC Filings

LH Valuation

P/E Current 25.443
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 23.986
Price to Sales Ratio 1.507
Price to Book Ratio 2.392
Price to Cash Flow Ratio 12.82
Enterprise Value to EBITDA 10.913
Enterprise Value to Sales 1.938
Total Debt to Enterprise Value 0.241

LH Efficiency

Revenue/Employee 196,502.817
Income Per Employee 12,345.07
Receivables Turnover 6.171
Total Asset Turnover 0.759

LH Liquidity

Current Ratio 1.424
Quick Ratio 1.235
Cash Ratio 0.189

LH Profitability

Gross Margin 26.753
Operating Margin 10.867
Pretax Margin 7.938
Net Margin 6.282
Return on Assets 4.767
Return on Equity 10.515
Return on Total Capital 5.787
Return on Invested Capital 6.133

LH Capital Structure

Total Debt to Total Equity 75.709
Total Debt to Total Capital 43.088
Total Debt to Total Assets 35.481
Long-Term Debt to Equity 67.637
Long-Term Debt to Total Capital 38.494
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Labcorp Holdings Inc. - LH

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
14.88B 12.16B 13.01B 13.95B
Sales Growth
-7.72% -18.25% +6.97% +7.25%
Cost of Goods Sold (COGS) incl D&A
10.75B 9.02B 9.64B 10.22B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
828.30M 580.90M 899.90M 961.10M
Depreciation
569.00M 361.10M 643.50M 681.10M
Amortization of Intangibles
259.30M 219.80M 256.40M 280.00M
COGS Growth
-1.06% -16.13% +6.93% +6.00%
Gross Income
4.13B 3.15B 3.37B 3.73B
Gross Income Growth
-21.48% -23.77% +7.09% +10.82%
Gross Profit Margin
+27.73% +25.86% +25.89% +26.75%
2022 2023 2024 2025 5-year trend
SG&A Expense
2.00B 2.02B 2.23B 2.22B
Research & Development
- - - -
-
Other SG&A
2.00B 2.02B 2.23B 2.22B
SGA Growth
+5.41% +1.24% +10.32% -0.61%
Other Operating Expense
- - - -
-
Unusual Expense
355.30M 398.10M 51.30M 142.60M
EBIT after Unusual Expense
1.77B 725.60M 1.09B 1.37B
Non Operating Income/Expense
(11.00M) 42.90M 81.10M (42.00M)
Non-Operating Interest Income
8.90M 28.80M 22.30M 15.20M
Equity in Earnings of Affiliates
5.40M (1.40M) (1.40M) (13.30M)
Interest Expense
180.30M 199.60M 208.30M 224.10M
Interest Expense Growth
-14.99% +10.70% +4.36% +7.59%
Gross Interest Expense
180.30M 199.60M 208.30M 224.10M
Interest Capitalized
- - - -
-
Pretax Income
1.58B 568.90M 959.50M 1.11B
Pretax Income Growth
-49.38% -64.05% +68.66% +15.42%
Pretax Margin
+10.64% +4.68% +7.38% +7.94%
Income Tax
302.00M 188.50M 212.40M 229.80M
Income Tax - Current - Domestic
229.50M 222.00M 172.10M 77.10M
Income Tax - Current - Foreign
65.30M 44.60M 60.40M 55.10M
Income Tax - Deferred - Domestic
2.40M (94.70M) (17.40M) 99.00M
Income Tax - Deferred - Foreign
4.80M 16.60M (2.70M) (1.40M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
5.40M (1.40M) (1.40M) (13.30M)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.28B 380.40M 747.10M 877.70M
Minority Interest Expense
1.50M 1.20M 1.10M 1.20M
Net Income
1.28B 379.20M 746.00M 876.50M
Net Income Growth
-46.20% -70.35% +96.73% +17.49%
Net Margin Growth
+8.60% +3.12% +5.73% +6.28%
Extraordinaries & Discontinued Operations
- - - 38.80M
-
Discontinued Operations
- - - 38.80M
-
Net Income After Extraordinaries
1.28B 418.00M 746.00M 876.50M
Preferred Dividends
- - - -
-
Net Income Available to Common
1.28B 418.00M 746.00M 876.50M
EPS (Basic)
14.0406 4.7991 8.8915 10.5349
EPS (Basic) Growth
-42.89% -65.82% +85.27% +18.48%
Basic Shares Outstanding
91.10M 87.10M 83.90M 83.20M
EPS (Diluted)
13.964 4.7717 8.8389 10.4594
EPS (Diluted) Growth
-42.73% -65.83% +85.24% +18.33%
Diluted Shares Outstanding
91.60M 87.60M 84.40M 83.80M
EBITDA
2.96B 1.70B 2.04B 2.48B
EBITDA Growth
-31.23% -42.36% +19.55% +21.56%
EBITDA Margin
+19.88% +14.02% +15.67% +17.76%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 312.25
Number of Ratings 20 Current Quarters Estimate 4.125
FY Report Date 03 / 2026 Current Year's Estimate 17.861
Last Quarter’s Earnings 4.07 Median PE on CY Estimate N/A
Year Ago Earnings 16.44 Next Fiscal Year Estimate 19.332
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 16 16 17 17
Mean Estimate 4.12 4.72 17.86 19.33
High Estimates 4.35 4.81 17.96 19.83
Low Estimate 3.97 4.32 17.58 18.80
Coefficient of Variance 2.11 2.48 0.61 1.42

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 13
OVERWEIGHT 2 2 3
HOLD 5 5 7
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Labcorp Holdings Inc. - LH

Date Name Shares Transaction Value
Feb 20, 2026 Amy B. Summy EVP, Chief Marketing Officer 5,805 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Sandra Danett van der Vaart EVP, Corporate Affairs 3,225 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Peter J. Wilkinson SVP, Chief Accounting Officer 1,968 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Peter J. Wilkinson SVP, Chief Accounting Officer 2,128 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Peter J. Wilkinson SVP, Chief Accounting Officer 2,518 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $289.89 per share 729,943.02
Feb 20, 2026 Peter J. Wilkinson SVP, Chief Accounting Officer 2,564 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Peter J. Wilkinson SVP, Chief Accounting Officer 2,404 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $289.89 per share 696,895.56
Feb 20, 2026 Peter J. Wilkinson SVP, Chief Accounting Officer 2,564 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Bryan Vaughn EVP, Diagnostics 5,613 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $289.89 per share 1,627,152.57
Feb 20, 2026 Mark S. Schroeder EVP, Pres Diagnostics & COO 6,473 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $289.89 per share 1,876,457.97
Feb 20, 2026 Bryan Vaughn EVP, Diagnostics 4,031 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Sandra Danett van der Vaart EVP, Corporate Affairs 1,141 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Julia Wang Chief Financial Officer, EVP 1,817 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $289.89 per share 526,730.13
Feb 20, 2026 Amy B. Summy EVP, Chief Marketing Officer 1,304 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Julia Wang Chief Financial Officer, EVP 2,062 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Mark S. Schroeder EVP, Pres Diagnostics & COO 6,732 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Mark S. Schroeder EVP, Pres Diagnostics & COO 2,358 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Bryan Vaughn EVP, Diagnostics 5,706 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Amy B. Summy EVP, Chief Marketing Officer 5,722 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $289.89 per share 1,658,750.58
Feb 20, 2026 Sandra Danett van der Vaart EVP, Corporate Affairs 3,126 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $289.89 per share 906,196.14

Labcorp Holdings Inc. in the News